Cargando…
Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults
PURPOSE: No standard salvage regimen is available for relapsed or refractory sarcoma. We investigated the efficacy and toxicity of the vincristine, irinotecan, and temozolomide combination (VIT) for relapsed or refractory sarcomas of variable histology in children and young adults. MATERIALS AND MET...
Autores principales: | Ju, Hee Young, Park, Meerim, Lee, Jun Ah, Park, Hyeon Jin, Park, Seog Yun, Kim, June Hyuk, Kang, Hyun Guy, Yang, Hee Chul, Park, Byung-Kiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016305/ https://www.ncbi.nlm.nih.gov/pubmed/34126703 http://dx.doi.org/10.4143/crt.2021.178 |
Ejemplares similares
-
Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022) -
A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors
por: Yoon, Jong Hyung, et al.
Publicado: (2014) -
A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors
por: Venkatramani, Rajkumar, et al.
Publicado: (2013) -
Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies
por: Wang, Bi-Cheng, et al.
Publicado: (2022) -
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2022)